Teva flogs Paragard for up to $1 billion

12 September 2017

Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has entered into a definitive agreement under which USA-based CooperSurgical will acquire intrauterine copper contraceptive Paragard, a product within its global Women's Health business, in a $1.1 billion cash transaction.

Paragard had revenues of approximately $168 million for the trailing 12-month period ending June 30, 2017. This transaction includes Teva's manufacturing facility in Buffalo, New York, which produces Paragard exclusively.

The move comes following speculation that Teva was looking to sell it Women’s Health business, and amid pricing pressure, falling profits and investors’ concerns that it had paid too much - $40 billion – for the Actavis generics business in 2015, and comes hot on the heels of its welcome announcement that it has at last found a new chief executive in the form of Lundbeck’s Kare Schultz.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK